SG3 Management’s Epizyme, Inc EPZM Stock Holding History

SG3 Management’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-8,710	Closed	-$76K	–	1460
2021 Q1	$76K	Buy	8,710 +3,710	+74%	+$38.4K	﹤0.01%	1069
2020 Q4	$54K	Buy	+5,000	New	+$61.7K	﹤0.01%	960

Other funds holding EPZM

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KXA

KPCB XIII Associates Menlo Park, California $186M AUM 11.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

SG3 Management's EPZM Position: Q2 2021 in Review

SG3 Management sold out of Epizyme, Inc (EPZM) in Q2 2021, closing a stake of 8,710 shares — an estimated $76K sold.

SG3 Management first reported a position in EPZM in Q4 2020 and held it in 2 quarters. The position peaked at $76K in Q1 2021. 126 funds tracked by Wall St. Rank hold EPZM as of Q2 2021.

SG3 Management reported no remaining Epizyme, Inc position as of Q2 2021 after selling out during the quarter.
SG3 Management sold 8,710 Epizyme, Inc shares in Q2 2021, an estimated $76K.
SG3 Management first reported a position in Epizyme, Inc in Q4 2020 and held it in 2 quarters.
SG3 Management's Epizyme, Inc position peaked at $76K in Q1 2021.
126 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2021.

Based on SG3 Management's 13F filing for Q2 2021, filed 16 Aug 2021.